No surprises. We'll probably see a press release this month when the VMAT-2 trial kicks off. Everything else is just one quarter closer to achieving their goals. I expect the stock to rise in anticipation of releasing the Uterine Fibroids Phase II data.
I have half of my investment money in this one stock. I'm OK hanging out here with it. Even though it gets badly beaten up on bad market days. You just know that sooner or later the anticipation of the clinical trials results will bring the stock up nicely. I am glad to see Elagolix completely in the hands of Abbott. They certainly have not over promised on the length of time required for Endometriosis and you expect that they will meet all the current established timelines. VMAT-2 could just work nicely as an additional driver. I'm happy things are moving along nicely.